SCHEMBL5465217

SCHEMBL5465217

CCCC(=O)Nc1sc2c(c1C(N)=O)CCCC2

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.81
SMN1; SMN2 Q16637 4/20 0.81
MEN1 O00255 2/20 0.81
KMT2A Q03164 2/20 0.81
RAB9A P51151 2/20 0.81
MAPK10 P53779 1/20 0.81
FLT3 P36888 5/20 0.80
KDM4E B2RXH2 2/20 0.76
MAPK1 P28482 1/20 0.76
HPGD P15428 5/20 0.74
MAPT P10636 4/20 0.74
LMNA P02545 3/20 0.71
CYP1A2 P05177 1/20 0.68
CYP2C19 P33261 1/20 0.68
TSHR P16473 4/20 0.68
GFER P55789 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
GAA P10253 1/20 0.65
HSD17B10 Q99714 2/20 0.64
ALOX15 P16050 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5457782 0.92 ALDH1A1 (0.95) ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL3125764 0.91 ALDH1A1 (0.88) ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL8288697 0.90 ALDH1A1 (0.86) ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL3453230 0.89 FLT3 (0.71) ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL4135422 0.89 HPGD (0.83) ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL5453467 0.89 FLT3 (1.00) ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL8288672 0.88 ALDH1A1 (0.93) ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL8288688 0.87 ALDH1A1 (0.91) ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL5454380 0.87 FLT3 (0.72) ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL5455950 0.86 HPGD (0.83) ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 ALDH1A1 1153/4885SMN1; SMN2 2157/4885MEN1 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.